Charles Schwab Investment Management Inc. Grows Stock Position in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Charles Schwab Investment Management Inc. lifted its holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO) by 2.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 948,451 shares of the company’s stock after purchasing an additional 23,675 shares during the period. Charles Schwab Investment Management Inc. owned about 0.72% of Organogenesis worth $2,713,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Acadian Asset Management LLC increased its stake in shares of Organogenesis by 2.4% in the 2nd quarter. Acadian Asset Management LLC now owns 3,074,375 shares of the company’s stock valued at $8,605,000 after purchasing an additional 72,696 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of Organogenesis by 76.9% in the 2nd quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company’s stock valued at $6,353,000 after purchasing an additional 986,132 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Organogenesis by 19.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company’s stock valued at $5,702,000 after purchasing an additional 333,123 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Organogenesis by 5.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 471,240 shares of the company’s stock valued at $1,348,000 after purchasing an additional 24,878 shares in the last quarter. Finally, Wealth Dimensions Group Ltd. boosted its holdings in Organogenesis by 435.9% in the 2nd quarter. Wealth Dimensions Group Ltd. now owns 407,965 shares of the company’s stock worth $1,142,000 after buying an additional 331,840 shares during the last quarter. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Insider Buying and Selling

In other news, CEO Gary S. Gillheeney sold 157,448 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $3.64, for a total transaction of $573,110.72. Following the transaction, the chief executive officer now directly owns 3,143,753 shares in the company, valued at $11,443,260.92. The trade was a 4.77 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders have sold 216,916 shares of company stock worth $784,832. Insiders own 36.90% of the company’s stock.

Organogenesis Trading Down 3.7 %

ORGO stock opened at $3.40 on Monday. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. Organogenesis Holdings Inc. has a 12-month low of $2.16 and a 12-month high of $4.70. The stock has a market cap of $450.77 million, a price-to-earnings ratio of -56.67 and a beta of 1.73. The business’s 50-day moving average is $3.43 and its 200 day moving average is $2.99.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.11. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The company had revenue of $115.18 million for the quarter, compared to analysts’ expectations of $109.59 million. During the same period in the previous year, the firm posted $0.02 EPS. On average, sell-side analysts anticipate that Organogenesis Holdings Inc. will post -0.07 EPS for the current fiscal year.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.